Sector Gamma AS Has $31.90 Million Stock Holdings in Pfizer Inc. $PFE

Sector Gamma AS raised its stake in Pfizer Inc. (NYSE:PFE) by 36.1% during the third quarter, HoldingsChannel reports. The institutional investor owned 1,252,086 shares of the biopharmaceutical company’s stock after acquiring an additional 332,086 shares during the period. Pfizer comprises about 7.9% of Sector Gamma AS’s investment portfolio, making the stock its largest position. Sector Gamma AS’s holdings in Pfizer were worth $31,903,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in the stock. Norges Bank bought a new stake in Pfizer in the second quarter valued at approximately $2,270,157,000. Vanguard Group Inc. boosted its stake in shares of Pfizer by 1.9% in the 2nd quarter. Vanguard Group Inc. now owns 533,363,457 shares of the biopharmaceutical company’s stock valued at $12,928,730,000 after purchasing an additional 10,198,330 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its position in shares of Pfizer by 43.4% during the second quarter. Arrowstreet Capital Limited Partnership now owns 18,718,955 shares of the biopharmaceutical company’s stock worth $453,747,000 after buying an additional 5,662,309 shares during the period. Assenagon Asset Management S.A. lifted its holdings in Pfizer by 75.0% in the third quarter. Assenagon Asset Management S.A. now owns 8,689,103 shares of the biopharmaceutical company’s stock valued at $221,398,000 after buying an additional 3,722,531 shares during the period. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its position in Pfizer by 84.9% during the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 7,561,946 shares of the biopharmaceutical company’s stock valued at $183,302,000 after acquiring an additional 3,472,240 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.

Pfizer Stock Performance

PFE opened at $25.65 on Friday. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $27.69. The company has a market cap of $145.82 billion, a price-to-earnings ratio of 14.91 and a beta of 0.47. The company’s fifty day moving average price is $25.40 and its two-hundred day moving average price is $25.01. The company has a current ratio of 1.28, a quick ratio of 0.97 and a debt-to-equity ratio of 0.62.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.79 by $0.08. Pfizer had a net margin of 15.65% and a return on equity of 20.17%. The firm had revenue of $16.65 billion during the quarter, compared to analysts’ expectations of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 23rd will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, January 23rd. This represents a $1.72 annualized dividend and a yield of 6.7%. Pfizer’s dividend payout ratio is 100.00%.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. Sanford C. Bernstein reaffirmed a “market perform” rating and set a $30.00 target price on shares of Pfizer in a research note on Friday, October 31st. UBS Group started coverage on shares of Pfizer in a research report on Tuesday, January 6th. They set a “neutral” rating and a $25.00 price objective for the company. TD Cowen reiterated a “hold” rating on shares of Pfizer in a research report on Tuesday, December 30th. The Goldman Sachs Group reissued a “neutral” rating and set a $26.00 target price on shares of Pfizer in a research note on Wednesday, November 5th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a report on Thursday. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Pfizer presently has an average rating of “Hold” and a consensus price target of $27.88.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: NICE recommended Pfizer’s PARP inhibitor Talzenna for adults with prostate cancer — a UK endorsement that supports incremental oncology revenue and validates Pfizer’s targeted‑therapy strategy. NICE backs Pfizer’s Talzenna for adults with prostate cancer
• Positive Sentiment: Pfizer launched a large Phase 3 lung‑cancer trial positioning its regimen against Merck’s Keytruda — a successful outcome would target a high‑value oncology market and materially boost long‑term growth expectations. Pfizer Takes Aim at Keytruda in New Phase 3 Lung Cancer Study: What Investors Should Know
• Positive Sentiment: Pfizer moved a COPD candidate into a Phase 2/3 trial, strengthening its post‑COVID respiratory pipeline and the company’s addressable market in chronic lung disease. Pfizer Advances New COPD Candidate Into Phase 2/3, Adding Depth to Its Post-COVID Pipeline
• Positive Sentiment: Novavax and Pfizer reached a licensing agreement on the Matrix‑M adjuvant — this could reshape Pfizer’s vaccine platform strategy by expanding adjuvant options and serviceable vaccine markets. Novavax inks license agreement with Pfizer
• Positive Sentiment: Early‑stage pipeline progress: PF‑07248144 advanced with a drug–interaction study and PF‑08065010 entered Phase 1 — steady, low‑visibility pipeline work that reduces binary risk over time. Pfizer Advances PF-07248144 With New Drug–Interaction Study, Signaling Quiet Pipeline Progress
• Neutral Sentiment: Large options flow: traders bought ~446,836 call options (≈+114% vs. typical volume) — indicates short‑term bullish/speculative positioning but not a direct fundamental signal. (Market data)
• Neutral Sentiment: CEO Albert Bourla publicly criticized RFK Jr.’s vaccine views and warned the U.S. risks falling behind China in health research — a strong management stance on science and policy that can influence regulatory/public perception but is not an immediate earnings driver. Pfizer CEO Calls RFK’s Vaccine Views Anti-Science, Warns US Falling Behind China In Health Research
• Negative Sentiment: Investor concerns persist on pricing and post‑COVID revenue sustainability — recent pieces question whether Pfizer’s current valuation reflects secular headwinds and pricing pressure, which helps explain selling pressure despite pipeline news. Is Pfizer (PFE) Pricing Make Sense After Post Covid Slowdown Concerns
• Negative Sentiment: Opinion pieces highlight a debate whether Pfizer is an attractive dividend/value play or a value trap — ongoing skepticism around growth prospects can keep the stock depressed. Is Pfizer an Absurdly Cheap Dividend Stock, or Just a Value Trap?

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.